For research use only; not for diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption & disposal requirements under European REACH regulations (EC 1907/2006).
Formats:
AlphaLISA features:
AlphaLISA technology allows the detection of molecules of interest in buffer, cell culture media, serum and plasma in a highly sensitive, quantitative, reproducible and user-friendly mode. In an AlphaLISA assay, a Biotinylated Anti-Analyte Antibody binds to the Streptavidin-coated Alpha Donor beads, while another Anti-Analyte Antibody is conjugated to AlphaLISA Acceptor beads. In the presence of the analyte, the beads come into close proximity. The excitation of the Donor beads provokes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm.
NFL is neurofilament light chain protein, also known as Neurofilament light polypeptide, 68 kDa neurofilament protein, Neurofilament triplet L protein, NEFL, NF68, CMT1F, and CMT2E. It is a 68 kDa subunit of the three so-called neurofilament triplet proteins: light (68 kDa), medium (160 kDa) and heavy (200 kDa), which are major structural components of neurons. High levels of neurofilament have been observed during the progression of numerous neurological diseases. Many studies have demonstrated that NFL can be used as a biomarker for disease monitoring in Amyotrophic Lateral Sclerosis (ALS), multiple sclerosis (MS) and Huntington's disease. It has also been shown to act as a tumor suppressor and has been linked to carcinogenesis/metastasis of several malignancies including breast, prostate, lung, colon, and bladder cancer.
| Assay Target | NFL |
|---|---|
| Assay Target Class | Protein |
| Automation Compatible | Yes |
| Detection Method | Alpha |
| Product Brand Name | AlphaLISA |
| Shipping Condition | Blue Ice |
| Therapeutic Area | Central Nervous System |
| Unit Size | 5,000 Assay Points |
The introduction of enzyme-linked immunosorbent assays (ELISAs) in the early 1970’s offered researchers a non-radiometric immunoassay platform without compromising sensitivity. Over the last 50 years scientists have made huge strides in disease research and drug discovery and a demand for greater assay throughput and sensitivity has evolved. In response, more robust immunoassays have been developed to address some of the limitations of the standard, colorimetric ELISA.
Find out about the most common limitations of traditional ELISAs and how different ELISA alternative technologies address these limitations.
Product brochure for the Alpha Technology, a versatile, no wash, homogeneous assay technology that's suitable for a broad range of applications.
Over these last few decades there has been a growing trend in drug discovery to use cellular systems and functional assays, in addition to biochemical assays, for the characterization of new potential therapeutics. The ability to study the interaction between a candidate drug and its target within the context of a whole, intact cell allows for more physiologically relevant data to be obtained. However, such assays are more complex than traditional biochemical assays as such facts as membrane permeability, cellular metabolism, cell variability, additional binding partners, and signal transduction must be considered.
To help you navigate the complexities in designing cell-based assays, we have gathered insights collected over the years and compiled them to provide you with elements to consider when setting up your cell-based assays. After all, any assay, biochemical or cell-based, is only as good as its design.
List Price : USD67.0
OptiPlate-384, White Opaque 384-well Microplate, Case 50
List Price : USD295.0
AlphaPlate-384, Light gray, untreated, Case of 50
List Price : USD546.0
